Crinetics Q2: PALSONIFY Revenue Ramps to $24M, Cash at $1.2B Ahead of Vertex Merger
CRNX has more than doubled off its 52-week low of $25.83.
Summary
Crinetics reported Q2 2026 revenue of $25.1 million, driven by $24 million in PALSONIFY sales, and ended the quarter with $1.2 billion in cash. The results land just weeks after Vertex agreed to acquire the company for $10 billion.
Key Events · Earnings and Guidance · CRNX
-
PALSONIFY Revenue Jumps to $24M
Net product revenue reached $24.0 million in Q2 2026, up from $10.3 million in Q1, driven by 245 new enrollment forms and over 70% of patients on reimbursed therapy.
-
Cash Position Remains Strong at $1.2B
Cash, equivalents, and investments totaled $1.2 billion as of June 30, 2026, providing ample liquidity through the expected close of the Vertex acquisition.
-
Regulatory Milestones Expand Global Reach
PALSONIFY received European Commission approval in April 2026, and marketing applications were submitted in Brazil (ANVISA) and Japan (SKK's NDA).
-
Merger with Vertex on Track for Q3 Close
The $10 billion all-cash acquisition at $85/share, announced July 6, is expected to close in Q3 2026, subject to shareholder and regulatory approvals. The 10-Q details merger-related risks and $2.3 million in accrued transaction costs.
Analysis · CRNX · Life Sciences
Crinetics' second-quarter results show PALSONIFY gaining commercial traction with $24 million in net product revenue, up from $10.3 million in Q1. The drug is now approved in both the U.S. and EU, with regulatory submissions in Brazil and Japan. The company burned $120.9 million in the quarter but holds $1.2 billion in cash and investments — ample runway through the expected close of its $10 billion acquisition by Vertex in the third quarter. The filing also details merger-related risks and $2.3 million in accrued transaction costs. For a company being acquired at $85 per share, the standalone financials matter less than the deal's progress, but the strong commercial launch and regulatory momentum reduce the risk of the deal falling apart.
At the time of this filing, CRNX was trading at $83.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $25.83 to $84.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.